MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
SNAP-8 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
SNAP-8 (Acetyl Octapeptide-3) is a topical cosmetic peptide developed as a structural extension of Argireline. Its eight-residue sequence mimics the N-terminal domain of SNAP-25, a SNARE protein required for calcium-dependent acetylcholine vesicle fusion at neuromuscular junctions. By competing with native SNAP-25 for incorporation into the SNARE complex, SNAP-8 destabilizes vesicle docking in superficial cutaneous nerve endings supplying facial mimetic muscles, producing a partial, reversible reduction in dynamic expression-line contraction. It is studied primarily for periocular and forehead wrinkle softening as a non-injectable alternative to botulinum toxin, with manufacturer-sponsored studies reporting roughly 30 to 35 percent reductions in wrinkle depth after 28 days of twice-daily use [PMID: 18494888][PMID: 22716242]. SNAP-8 is regulated as a cosmetic ingredient, not an approved drug, and is never administered by injection.
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Cosmetic regulatory status: SNAP-8 is regulated globally as a cosmetic ingredient and is sold under trade names by Lubrizol/Lipotec. It has no drug approval and no recognized injectable, oral, or systemic indication in any jurisdiction.
Typical formulation strength: Commercial serums and creams contain 5 to 10 percent acetyl octapeptide-3 by weight, applied as a thin twice-daily layer to forehead, glabella, and crow's-feet, often combined with Argireline, Matrixyl, or GHK-Cu.
Negligible systemic absorption: Its 890 Da hydrophilic structure penetrates the stratum corneum poorly, so systemic exposure is essentially zero. This removes the dysphagia and ptosis risks associated with botulinum toxin but also limits potency.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
Interactive SNAP-8 Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 330 mcg (0.33 mg) | 10 units (0.10 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 (Optional) | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (SNAP-8, 10 mg each):
- check8 weeks ≈ 3 vials
- check12 weeks ≈ 6 vials
- check16 weeks ≈ 8 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- check12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- check16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
SNAP-8 (Acetyl Octapeptide-3) has the amino acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 and is a structural extension of the hexapeptide Argireline (Acetyl Hexapeptide-3). Both peptides are designed to mimic the N-terminal domain of SNAP-25, a synaptosomal-associated protein of 25 kDa that forms part of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex. The SNARE complex, composed of SNAP-25, syntaxin, and synaptobrevin (VAMP), is essential for docking and fusion of acetylcholine-containing vesicles at the presynaptic membrane of motor neurons innervating skeletal muscle, including the facial mimetic muscles responsible for expression lines such as forehead furrows, glabellar lines, and crow's feet [1][2]. By competing with native SNAP-25 for incorporation into the SNARE complex, SNAP-8 destabilizes vesicle docking and reduces the calcium-dependent exocytosis of acetylcholine. The result is a localized, partial reduction in muscle contraction intensity without producing the complete chemodenervation associated with botulinum neurotoxin type A, which cleaves SNAP-25 enzymatically and produces sustained paralysis lasting months [3]. SNAP-8 acts non-enzymatically, reversibly, and only on superficial cutaneous tissue, since the peptide does not penetrate beyond the dermis in significant quantities and is rapidly degraded by tissue peptidases. In vitro receptor-free assays demonstrate that SNAP-8 inhibits catecholamine release from chromaffin cells and reduces vesicular fusion in synaptosomal preparations, supporting the mechanistic rationale for muscle-relaxant effects. The molecule is acetylated at the N-terminus to improve stability against aminopeptidases and amidated at the C-terminus to enhance binding affinity. Its octapeptide length confers greater receptor specificity than the parent hexapeptide and, according to in vitro comparisons sponsored by the original developer Lipotec (now Lubrizol), produces approximately 30% greater inhibition of muscle contraction at equimolar concentrations than Argireline. Beyond neuromuscular signaling, SNAP-8 has been hypothesized to modulate keratinocyte function and exert mild antioxidant effects through its glutamate-rich domain, though these pathways are poorly characterized in peer-reviewed literature. Importantly, SNAP-8 has very limited dermal penetration: its high polarity (multiple charged residues), molecular weight near 890 Da, and hydrophilic character mean that only a small fraction crosses the stratum corneum. Penetration enhancers, liposomal carriers, or micellar formulations are typically employed in commercial cosmetic products to deliver the peptide to deeper layers of the epidermis where it can interact with cutaneous nerve endings supplying mimetic muscle fibers. Clinical and instrumental studies in human volunteers report reductions in wrinkle depth and roughness parameters measured by silicone replica analysis and profilometry after 28–60 days of twice-daily topical application of 5–10% SNAP-8 formulations [4]. The effect is gradual, cumulative, and fully reversible upon discontinuation, with no measurable systemic absorption and no documented effect on neuromuscular function outside the area of application.
Clinical Trial Efficacy Highlights
- starA vehicle-controlled clinical evaluation of 10% acetyl octapeptide-3 cream applied twice daily for 28 days demonstrated a mean reduction in wrinkle depth of 34.98% on forehead expression lines compared to baseline silicone replica measurements, with most subjects reporting visible smoothing within two to four weeks of consistent use [4].
- starManufacturer-sponsored in vitro comparisons against Argireline (acetyl hexapeptide-3) at equimolar concentrations indicate that SNAP-8 produces roughly 30% greater inhibition of catecholamine vesicular release from chromaffin cell preparations, suggesting enhanced affinity for the SNARE complex docking site and supporting the rationale for its development as a next-generation cosmetic peptide [2].
- starProfilometric and image-analysis studies of 5% SNAP-8 emulsions used twice daily for 60 days show statistically significant reductions in dynamic crow's-feet wrinkle scores compared with vehicle, with subject self-assessment generally favoring the active formulation, although effect sizes are modest compared with botulinum toxin injections [1].
- starReviews in the Journal of Cosmetic Dermatology and the International Journal of Cosmetic Science classify SNAP-8 among the peptides with the strongest mechanistic rationale and best in vitro evidence among topical neuromodulating cosmetic peptides, while emphasizing that independent, large-scale, randomized comparative trials remain limited [1].
- starTolerability data from cosmetic safety panels indicate very low rates of cutaneous irritation, sensitization, or contact dermatitis with SNAP-8 at concentrations up to 10%, supporting routine inclusion in eye contour and forehead anti-aging products without restrictions on long-term daily use [4].
- starSystemic exposure studies are essentially absent because penetration through intact skin into circulation is negligible for an 890-Da hydrophilic octapeptide; this pharmacokinetic profile supports the regulatory classification of SNAP-8 as a cosmetic ingredient rather than a transdermal drug and removes the muscle-paralysis safety concerns associated with botulinum toxin [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningTopical SNAP-8 is generally very well tolerated, with the most commonly reported adverse effects limited to mild, transient erythema, stinging, or a sensation of tightness at the site of application, particularly when used with other actives such as retinoids or alpha-hydroxy acids.
- warningAllergic contact dermatitis to SNAP-8 itself is rare, but reactions to other components of the finished cosmetic formulation, including preservatives, fragrances, or penetration enhancers, can produce eczematous patches and should be evaluated by a dermatologist if persistent.
- warningBecause SNAP-8 is intended for topical periocular and forehead use, accidental ocular contact may cause transient conjunctival irritation, watering, and burning; the product should be kept away from the eye margin and rinsed promptly with water if it migrates onto the ocular surface.
- warningThere is no published evidence that SNAP-8 produces systemic muscle weakness, dysphagia, ptosis, or other neuromuscular adverse events characteristic of botulinum toxin, since the peptide is too large and polar to be absorbed into systemic circulation through intact skin in pharmacologically active amounts.
- warningSafety data in pregnancy, lactation, and pediatric use are absent; on a precautionary basis, manufacturers and cosmetic regulators generally recommend avoiding SNAP-8-containing products during pregnancy and breastfeeding despite the very low theoretical risk of systemic exposure.
- warningOveruse, application to broken or inflamed skin, or combination with potent exfoliants can increase the risk of irritation and barrier dysfunction; users should follow product instructions and introduce SNAP-8 serums gradually into a skincare routine.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical SNAP-8 dosage?expand_more
SNAP-8 is exclusively a topical cosmetic ingredient. Commercial serums and creams typically contain 5–10% acetyl octapeptide-3 by weight, applied as a thin layer to clean skin on the forehead, glabella, and crow's-feet area twice daily. SNAP-8 is not administered by injection or any systemic route.
How is SNAP-8 administered?expand_more
SNAP-8 is applied topically as part of a leave-on serum, cream, or eye contour product. After cleansing, a pea-sized amount is gently massaged into target expression lines morning and evening, allowed to absorb fully, and followed by moisturizer and sunscreen as part of a normal anti-aging skincare routine.
Can SNAP-8 be combined with other compounds?expand_more
SNAP-8 is frequently combined in cosmetic formulations with Argireline, Matrixyl, GHK-Cu copper peptide, hyaluronic acid, niacinamide, and antioxidants. It is generally compatible with retinoids and vitamin C, although stacking multiple potent actives at once can increase the risk of irritation.
What are the side effects of SNAP-8?expand_more
Topical SNAP-8 is very well tolerated. Possible side effects are limited to mild, transient erythema, stinging, or tightness at the application site. Allergic contact dermatitis is uncommon. No systemic side effects have been reported because absorption through intact skin is negligible.
Is SNAP-8 FDA approved?expand_more
SNAP-8 is not an FDA-approved drug. It is regulated as a cosmetic ingredient in the United States and European Union, marketed under trade names such as SNAP-8 by Lubrizol/Lipotec. It does not undergo formal drug-style approval but must comply with cosmetic safety regulations.
Academic References & Study Citations
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. View Scientific Paper →
Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. View Scientific Paper →
Lim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Sci Rep. 2018;8(1):1596. View Scientific Paper →
Reddy BY, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part II. Exp Dermatol. 2012;21(8):569-575. View Scientific Paper →
Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. View Scientific Paper →
Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. View Scientific Paper →
Errante F, Ledwon P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:572923. View Scientific Paper →
Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. View Scientific Paper →
Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF. Trending anti-aging peptides. Cosmetics. 2020;7(4):91. View Scientific Paper →